


Name: LI-2242 cat#: EX-A13496

Target: IPK Superfamily

Pathway: Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Chemical Structure:



Chemical Name	Spiro[3H-indole-3,4'-piperidine]-5-carboxylic acid, 1'-[(2,4-dichlorophenyl)methyl]-1,2-dihydro-2-oxo-		
---------------	--	--	--

Molecular Weight	405.275	Storage	2 years 4°C powder
Formula	C ₂₀ H ₁₈ Cl ₂ N ₂ O ₃		3 years -20°C powder
CAS No.	2762762-17-2		6 months -80°C in solvent
		Synonyms	LI2242; LI 2242

Solubility (25°C) *	In vitro	DMSO	DMSO : >50 mg/mL
		Ethanol	N/A
		Water	N/A
	In vivo (should be freshly prepared each time)	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (12.34 mM); Clear solution	
		2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (12.34 mM); Clear solution	

* <1 mg/ml means slightly soluble or insoluble.
 * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Concentration \ Mass Volume	Mass	1 mg	5 mg	10 mg
	Volume			
1 mM		2.4675 mL	12.3375 mL	24.6749 mL
5 mM		0.4935 mL	2.4675 mL	4.9350 mL
10 mM		0.2467 mL	1.2337 mL	2.4675 mL

DMSO :

*The above data is based on the product molecular weight 405.27.

Biological Activities:

Description:	LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC ₅₀ values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for the research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders ^[1] .
IC₅₀ & Target IC₅₀:	1 nM (IP6K1); 42 nM (IP6K2); 8.7 nM (IP6K3); 1944 nM (IPMK) ^[1] .
In Vitro:	LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC ₅₀ values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively ^[1] .

References

[1]. [Liao G, et al. Identification of Small-Molecule Inhibitors of Human Inositol Hexakisphosphate Kinases by High-Throughput Screening. ACS Pharmacol Transl Sci. 2021;4\(2\):780-789. Published 2021 Mar 3.](#)